Evidence map›Paper›PMID 34656159›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

The novel circSLC6A6/miR-1265/C2CD4A axis promotes colorectal cancer growth by suppressing p53 signaling pathway.

Zeyin Rong, Zai Luo, Zhongmao Fu, Pengshan Zhang, Tengfei Li, Jianming Zhang, Zhonglin Zhu, Zhilong Yu, Qi Li, Zhengjun Qiu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Aging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zeyin Rong *Department of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Zai Luo *Department of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Zhongmao Fu *Department of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Pengshan Zhang *Department of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Tengfei LiDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Jianming ZhangDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Zhonglin ZhuDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Zhilong YuDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Qi LiDepartment of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhengjun QiuDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China.
Chen HuangDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 100 Hai Ning Road, Hongkou District, Shanghai, 200080, China. richard-hc@hotmail.com.
Shanghai First People's Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

national natural science foundation of china 81772526national natural science foundation of china 82072662
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is one of the most frequent malignancy and a leading cause of cancer-related deaths. Therefore, further researches are required to identify novel and more effective diagnoses and to identify molecular targets in treatment of CRC.

methodsC2CD4A expression in CRC tissues and cell lines was detected by qRT-PCR and western blot. The biological functions of C2CD4A were performed both in vitro and in vivo. Western blot, cDNA array, IP-MS, Co-immunoprecipitation assay, and Ubiquitination assay were used to analyze the interaction between C2CD4A and p53. Bioinformatics analysis, FISH, RNA sequencing, luciferase reporter assay, RNA immunoprecipitation, RNA pull-down and rescue experiments, were deployed to detect upstream regulation mechanism of C2CD4A.

resultsC2CD4A was elevated in CRC tissues compared with adjacent normal colorectal tissues. C2CD4A knockdown significantly promoted cell apoptosis and with inhibited proliferation in vitro, and tumorigenicity in vivo, whereas C2CD4A overexpression led to opposite effects. Moreover, circSLC6A6 was upregulated and shown to positively regulate C2CD4A expression via sponging miR-1265. Fundamentally, C2CD4A inhibited p53 signaling pathway through interacting with p53 and increasing its ubiquitination and degradation.

conclusionOur results identified that circSLC6A6/miR-1265/C2CD4A axis, which was involved in CRC via the p53 signaling pathway, may serve as a therapeutic target for CRC.

Indexed as

AnimalsColorectal NeoplasmsHEK293 CellsHeterograftsHumansMaleMembrane GlycoproteinsMembrane Transport ProteinsMiceMice, Inbred BALB CMice, NudeMicroRNAsNuclear ProteinsSignal TransductionTaurine TransportersTranscription FactorsC2CD4A protein, humanMembrane GlycoproteinsMembrane Transport ProteinsMicroRNAsMIRN1265 microRNA, humanNuclear ProteinsTaurine TransportersTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53C2CD4AcircSLC6A6Colorectal cancermiR-1265p53

Identifiers

PMID34656159
PMCPMC8520208
OpenAlexW3176356463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.